A Receptor, a Vitamin, and the MS Differential

A metabolite measurement in multiple sclerosis (MS) is only as good as the design it sits inside. The same number, a concentration in plasma or cerebrospinal fluid, can be a readout of something causal, a marker of how ill someone already is, or an artefact of who agreed to take part. Five human studies from 2025 and 2026 show the range, and reading them in order of what each design licenses is more useful than reading them by how interesting the molecule is. One follows an autoantibody to a blocked receptor to a missing metabolite in the right compartment, then gives the metabolite back. Two build a metabolite clock, show it runs fast in MS, and then move it with diet while a third intervention leaves it alone. And two measure metabolites against disability without an intervention, and are explicit about what that cannot settle.

A Blocked Receptor, a Missing Metabolite, a Phenotype
Pluvinage and colleagues started from a clinical gap rather than from a molecule: between 12% and 18% of myelopathy cases never get an aetiological diagnosis, which is a problem MS clinicians meet from the other direction every time they work through a differential. Proteome-wide phage display on biofluids from 148 patients with idiopathic myelopathy turned up autoantibodies against CD320, the transcobalamin receptor that carries vitamin B12 into cells. Then they measured the metabolite downstream of the receptor, in the compartment where it would matter: bioactive vitamin B12 in cerebrospinal fluid was 15.1 pmol/L in antibody-positive patients against 22.9 pmol/L in neurological controls. A deficiency restricted to the central nervous system, produced by an antibody rather than by diet, and measured rather than inferred.

What Made That One Different
The chain has four links and each was tested separately. The antibody was found in 18 of 32 patients in the discovery cohort, and in two independent validation cohorts of 91 and 25 patients at 45% and 48%, so the prevalence held up outside the sample it was discovered in. The antibody-positive patients had a distinguishable clinical picture, with a subacute course in 56% against 7%, a normal cerebrospinal fluid profile in 83% against 50%, and dorsolateral spinal cord abnormalities on MRI in 61% against 7%. Five antibody-positive patients then received vitamin B12 supplementation, with or without immunosuppression, and four of five improved. Discovery, confirmation in separate cohorts, a phenotype, a measured metabolite deficit and a response to replacing it. The cohort is idiopathic myelopathy rather than MS, which is exactly why it belongs in an MS reading list.

A Metabolite Clock That Runs Fast
Siavoshi and colleagues built the next result in two steps, and the first step is the measurement. Using an aging clock derived from 11,977 healthy adults, they calculated metabolomic age in 323 patients against 66 healthy controls, and separately in 71 treatment-naive patients against 101 controls. Patients ran 9.77 years ahead of their chronological age, with a confidence interval of 6.57 to 12.97 and a p-value of 5.3 x 10^-9, and the treatment-naive group ran 4.90 years ahead, which keeps the finding from being an artefact of drug treatment. Longitudinally the patients aged 1.19 metabolomic years per chronological year. A 10-percentile rise in area deprivation index added 0.63 years of acceleration, putting a social gradient on a blood measurement. The authors note that the clock correlates only modestly with chronological age, at an R of roughly 0.20 to 0.25.

And Two Diets That Move It, While a Third Does Not
The second step is where the metabolite stops being a description. Reanalysing two completed dietary interventions, the same group found metabolomic age fell after a six-month modified ketogenic diet in 39 participants, at a p-value of 0.009, and after intermittent calorie restriction in an eight-week randomized comparison of 36 participants, at 0.04. The arm that matters most is the one that did nothing: daily calorie reduction, inside that same randomized comparison, had no effect on the clock. So the result is not simply that eating less moves the measurement. Two regimens that involve periods without food moved it and one that spreads the same restriction across every day did not, and the contrast sits inside one randomization rather than between studies. These are secondary analyses of trials run for other endpoints, which the authors state.

A Rewired Network, and a Year on One Arm
Wicks and colleagues compared 53 patients with severe progressive MS needing skilled nursing against 53 community-dwelling progressive patients matched for age, sex and disease duration. The severe group had lower HDL cholesterol, ApoA-I and ApoA-II, higher ApoB and ApoE, lower albumin and higher GlycA, and the result past group means came from difference-correlogram analysis: ApoE associated with lipid and nutritional markers in the severe group but with neurofilament light chain and glial fibrillary acidic protein in the controls. García Gañán and colleagues followed 41 patients for a year on dietary counselling, scoring adherence from 2 to 6; plasma homocysteine fell from 10.91 to 8.24 micromol/L by 6 months, and disability trajectories split by adherence, with adherence correlating inversely with disability change at r of -0.57.

What Each Design Buys
Put them side by side and the molecules matter less than the architecture around them. Pluvinage and colleagues can say a metabolite deficit is caused by something and corrected by something, because they have the antibody, the receptor, the compartment-specific measurement, independent cohorts and five treated patients. Siavoshi and colleagues can say a metabolite composite is raised in MS independently of treatment and that two fasting-type regimens lower it while a matched non-fasting restriction does not, which is a moved measurement with an internal control, though not a clinical outcome. Wicks and colleagues can say a lipid network is reorganised in severe disease, but cannot separate what disrupted the lipids from what being severely disabled and nutritionally depleted does to them. García Gañán and colleagues point out themselves that their adherence score was never validated, that it may reflect broader health behaviours or engagement with care, that the diet was individualized so no component can be named, and that causality cannot be inferred.

Disclaimer: This blog post is based on the cited studies and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.

References:
Pluvinage, J. V., Acero-Garces, D., Greco, G., et al., Gastaldi, M., Pardo, C. A., & Wilson, M. R. (2026). Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.2778
Siavoshi, F., Smith, M. D., Cassard, S., Moreau, G. B., Brenton, J. N., Mowry, E. M., Fitzgerald, K. C., & Bhargava, P. (2025). Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis. Annals of Neurology, 98(6), 1278–1282. https://doi.org/10.1002/ana.78044
Siavoshi, F., Noroozi, R., Chang, G., et al., Calabresi, P. A., Bhargava, P., & Fitzgerald, K. C. (2026). Accelerated metabolomic aging and its association with social determinants of health in multiple sclerosis. Multiple Sclerosis, 32(4), 421–428. https://doi.org/10.1177/13524585261417120
Wicks, T. R., Shittu, M., Wolska, A., Ghazal, D., Weinstock-Guttman, B., Burnham, A., Remaley, A. T., Zivadinov, R., & Ramanathan, M. (2026). Dysregulated Cholesterol Metabolism, Chronic Inflammation, and Disability in Severe Progressive Multiple Sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70550
García Gañán, D., Sanz Andreu, L., El Berdei Montero, Y., & Velasco Criado, A. (2026). Dietary adherence and disability evolution in multiple sclerosis: An exploratory 12-month prospective cohort study. Clinical Nutrition ESPEN, 75, 103462. https://doi.org/10.1016/j.clnesp.2026.103462